Bluebird Bio Stock Z Score

BLUE Stock

USD 0.97 0.02 2.11%

Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Check out Bluebird Bio Piotroski F Score and Bluebird Bio Valuation analysis.

For information on how to trade Bluebird Stock refer to our How to Trade Bluebird Stock guide.

At present, Bluebird Bio's Long Term Debt To Capitalization is projected to increase slightly based on the last few years of reporting. The current year's Total Debt To Capitalization is expected to grow to 0.56, whereas Capital Lease Obligations is forecasted to decline to about 186.3 M. At present, Bluebird Bio's Total Revenue is projected to increase significantly based on the last few years of reporting. The current year's Other Operating Expenses is expected to grow to about 385.4 M, whereas Selling General Administrative is forecasted to decline to about 125.4 M.

Bluebird bio Company Z Score Analysis

Bluebird Bio's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..

Z Score

Sum Of

5 Factors

More About Z Score | All Equity Analysis

First Factor

1.2 * (

Working Capital

/

Total Assets )

Second Factor

1.4 * (

Retained Earnings

/

Total Assets )

Thrid Factor

3.3 * (

EBITAD

/

Total Assets )

Fouth Factor

0.6 * (

Market Value of Equity

/

Total Liabilities )

Fifth Factor

0.99 * (

Revenue

/

Total Assets )

Bluebird Z Score Driver Correlations

Understanding the fundamental principles of building solid financial models for Bluebird Bio is extremely important. It helps to project a fair market value of Bluebird Stock properly, considering its historical fundamentals such as Z Score. Since Bluebird Bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bluebird Bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bluebird Bio's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Net Tangible Assets	Long Term Debt	Net Receivables	Good Will	Capital Surpluse	Deferred Long Term Liab	Intangible Assets	Long Term Investments	Long Term Debt Total	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.96	0.56	-0.42	-0.27	0.51	0.93	0.7	0.94	0.06	0.46	0.52	0.94	0.7	0.64	0.84	0.56	-0.32	0.5	0.75	0.65	0.64	0.13	0.09	-0.09
Total Stockholder Equity	0.96		0.67	-0.6	-0.07	0.38	0.95	0.57	0.98	-0.15	0.25	0.31	0.99	0.6	0.52	0.83	0.42	-0.32	0.59	0.84	0.51	0.52	0.35	0.3	-0.26
Current Deferred Revenue	0.56	0.67		-0.78	0.27	0.03	0.56	0.07	0.69	-0.44	-0.05	-0.06	0.65	0.08	0.0	0.49	-0.01	-0.46	0.48	0.52	0.07	0.09	0.51	0.47	-0.45
Net Debt	-0.42	-0.6	-0.78		-0.53	0.24	-0.44	0.18	-0.67	0.64	0.37	0.36	-0.62	0.06	0.23	-0.44	0.25	0.25	-0.54	-0.55	0.12	0.1	-0.71	-0.7	0.68
Retained Earnings	-0.27	-0.07	0.27	-0.53		-0.79	-0.12	-0.74	-0.06	-0.68	-0.91	-0.77	-0.01	-0.77	-0.7	-0.16	-0.91	0.41	0.2	0.16	-0.83	-0.82	0.88	0.9	-0.84
Accounts Payable	0.51	0.38	0.03	0.24	-0.79		0.47	0.88	0.38	0.48	0.73	0.63	0.33	0.85	0.68	0.38	0.88	-0.42	0.04	0.07	0.85	0.86	-0.55	-0.58	0.52
Short Term Investments	0.93	0.95	0.56	-0.44	-0.12	0.47		0.65	0.92	-0.12	0.22	0.28	0.96	0.59	0.65	0.77	0.46	-0.29	0.47	0.76	0.5	0.52	0.33	0.29	-0.25
Total Liab	0.7	0.57	0.07	0.18	-0.74	0.88	0.65		0.56	0.48	0.74	0.78	0.53	0.91	0.82	0.5	0.9	-0.37	0.08	0.26	0.91	0.92	-0.42	-0.45	0.52
Total Current Assets	0.94	0.98	0.69	-0.67	-0.06	0.38	0.92	0.56		-0.19	0.23	0.29	0.98	0.59	0.47	0.79	0.41	-0.38	0.54	0.76	0.52	0.54	0.34	0.31	-0.27
Short Term Debt	0.06	-0.15	-0.44	0.64	-0.68	0.48	-0.12	0.48	-0.19		0.78	0.73	-0.23	0.49	0.46	0.21	0.53	0.13	0.06	-0.28	0.5	0.47	-0.77	-0.76	0.75
Common Stock	0.46	0.25	-0.05	0.37	-0.91	0.73	0.22	0.74	0.23	0.78		0.9	0.16	0.8	0.68	0.41	0.87	-0.35	0.08	0.03	0.84	0.81	-0.79	-0.81	0.77
Property Plant Equipment	0.52	0.31	-0.06	0.36	-0.77	0.63	0.28	0.78	0.29	0.73	0.9		0.25	0.78	0.58	0.38	0.78	-0.2	0.03	0.16	0.83	0.8	-0.66	-0.69	0.7
Net Tangible Assets	0.94	0.99	0.65	-0.62	-0.01	0.33	0.96	0.53	0.98	-0.23	0.16	0.25		0.55	0.48	0.78	0.37	-0.3	0.54	0.85	0.46	0.48	0.41	0.37	-0.33
Long Term Debt	0.7	0.6	0.08	0.06	-0.77	0.85	0.59	0.91	0.59	0.49	0.8	0.78	0.55		0.75	0.55	0.94	-0.37	0.18	0.38	0.97	0.97	-0.47	-0.51	0.54
Net Receivables	0.64	0.52	0.0	0.23	-0.7	0.68	0.65	0.82	0.47	0.46	0.68	0.58	0.48	0.75		0.53	0.81	-0.29	0.14	0.24	0.71	0.71	-0.35	-0.37	0.43
Good Will	0.84	0.83	0.49	-0.44	-0.16	0.38	0.77	0.5	0.79	0.21	0.41	0.38	0.78	0.55	0.53		0.4	-0.28	0.86	0.64	0.44	0.43	0.14	0.12	-0.13
Capital Surpluse	0.56	0.42	-0.01	0.25	-0.91	0.88	0.46	0.9	0.41	0.53	0.87	0.78	0.37	0.94	0.81	0.4		-0.52	0.02	0.16	0.95	0.95	-0.64	-0.68	0.71
Deferred Long Term Liab	-0.32	-0.32	-0.46	0.25	0.41	-0.42	-0.29	-0.37	-0.38	0.13	-0.35	-0.2	-0.3	-0.37	-0.29	-0.28	-0.52		-0.16	-0.02	-0.45	-0.47	0.2	0.23	-0.25
Intangible Assets	0.5	0.59	0.48	-0.54	0.2	0.04	0.47	0.08	0.54	0.06	0.08	0.03	0.54	0.18	0.14	0.86	0.02	-0.16		0.53	0.03	0.04	0.33	0.32	-0.31
Long Term Investments	0.75	0.84	0.52	-0.55	0.16	0.07	0.76	0.26	0.76	-0.28	0.03	0.16	0.85	0.38	0.24	0.64	0.16	-0.02	0.53		0.23	0.25	0.46	0.41	-0.38
Long Term Debt Total	0.65	0.51	0.07	0.12	-0.83	0.85	0.5	0.91	0.52	0.5	0.84	0.83	0.46	0.97	0.71	0.44	0.95	-0.45	0.03	0.23		1.0	-0.56	-0.6	0.61
Short Long Term Debt	0.64	0.52	0.09	0.1	-0.82	0.86	0.52	0.92	0.54	0.47	0.81	0.8	0.48	0.97	0.71	0.43	0.95	-0.47	0.04	0.25	1.0		-0.54	-0.57	0.6
Net Invested Capital	0.13	0.35	0.51	-0.71	0.88	-0.55	0.33	-0.42	0.34	-0.77	-0.79	-0.66	0.41	-0.47	-0.35	0.14	-0.64	0.2	0.33	0.46	-0.56	-0.54		1.0	-0.9
Net Working Capital	0.09	0.3	0.47	-0.7	0.9	-0.58	0.29	-0.45	0.31	-0.76	-0.81	-0.69	0.37	-0.51	-0.37	0.12	-0.68	0.23	0.32	0.41	-0.6	-0.57	1.0		-0.9
Capital Stock	-0.09	-0.26	-0.45	0.68	-0.84	0.52	-0.25	0.52	-0.27	0.75	0.77	0.7	-0.33	0.54	0.43	-0.13	0.71	-0.25	-0.31	-0.38	0.61	0.6	-0.9	-0.9

Click cells to compare fundamentals

To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.

Competition

Predict Bluebird Bio

In accordance with the company's disclosures, Bluebird bio has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.

Bluebird Z Score Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bluebird Bio's direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bluebird Bio could also be used in its relative valuation, which is a method of valuing Bluebird Bio by comparing valuation metrics of similar companies.

Bluebird Bio is currently under evaluation in z score category among related companies.

Bluebird Bio Institutional Holders

Institutional Holdings refers to the ownership stake in Bluebird Bio that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Bluebird Bio's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Bluebird Bio's value.

		Shares
Dimensional Fund Advisors, Inc.	2023-12-31	3 M
Two Sigma Investments Llc	2023-12-31	2.9 M
Ameriprise Financial Inc	2023-12-31	2.8 M
Renaissance Technologies Corp	2023-12-31	2.6 M
Goldman Sachs Group Inc	2023-12-31	2.6 M
Bleichroeder Lp	2023-12-31	2.5 M
Fmr Inc	2023-12-31	2.4 M
Geode Capital Management, Llc	2023-12-31	2.4 M
Hudson Bay Capital Management Lp	2023-12-31	2.2 M
State Street Corporation	2023-12-31	13.9 M
Blackrock Inc	2023-12-31	9 M

Bluebird Fundamentals

	Return On Equity	-0.48
	Return On Asset	-0.15
	Operating Margin	(6.84) %
	Current Valuation	235.54 M
	Shares Outstanding	192.74 M
	Shares Owned By Insiders	0.37 %
	Shares Owned By Institutions	65.06 %
	Number Of Shares Shorted	29.75 M
	Price To Earning	(19.32) X
	Price To Book	0.96 X
	Price To Sales	9.76 X
	Revenue	21.73 M
	Gross Profit	(247.24 M)
	EBITDA	(131.77 M)
	Net Income	(91.17 M)
	Cash And Equivalents	132.51 M
	Cash Per Share	1.72 X
	Total Debt	281.39 M
	Debt To Equity	1.63 %
	Current Ratio	1.12 X
	Book Value Per Share	2.08 X
	Cash Flow From Operations	(277.48 M)
	Short Ratio	2.99 X
	Earnings Per Share	(0.63) X
	Price To Earnings To Growth	0.32 X
	Target Price	4.16
	Number Of Employees	323
	Beta	0.8
	Market Capitalization	187.08 M
	Total Asset	554.9 M
	Retained Earnings	(3.99 B)
	Working Capital	71.25 M
	Current Asset	523.97 M
	Current Liabilities	40.37 M
	Net Asset	554.9 M

About Bluebird Bio Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Bluebird bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bluebird Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bluebird bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Pair Trading with Bluebird Bio

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bluebird Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bluebird Bio will appreciate offsetting losses from the drop in the long position's value.

Moving together with Bluebird Stock

0.61	VKTX	Viking Therapeutics Earnings Call Today	Pair Corr
0.65	ENVB	Enveric Biosciences Financial Report 20th of May 2024	Pair Corr

Moving against Bluebird Stock

0.43

ACB

Aurora Cannabis Trending

Pair Corr

The ability to find closely correlated positions to Bluebird Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bluebird Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bluebird Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bluebird bio to buy it.

The correlation of Bluebird Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bluebird Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bluebird bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Bluebird Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Bluebird bio is a strong investment it is important to analyze Bluebird Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bluebird Bio's future performance. For an informed investment choice regarding Bluebird Stock, refer to the following important reports:

How To Invest In Bluebird

Details

Is Bluebird Stock a good investment?

Details

What is Bluebird Bio's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Bluebird Bio Piotroski F Score and Bluebird Bio Valuation analysis.

For information on how to trade Bluebird Stock refer to our How to Trade Bluebird Stock guide.

You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Complementary Tools for Bluebird Stock analysis

When running Bluebird Bio's price analysis, check to measure Bluebird Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bluebird Bio is operating at the current time. Most of Bluebird Bio's value examination focuses on studying past and present price action to predict the probability of Bluebird Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bluebird Bio's price. Additionally, you may evaluate how the addition of Bluebird Bio to your portfolios can decrease your overall portfolio volatility.

	Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
	Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
	Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk
	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios
	USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA
	Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
	Technical Analysis Check basic technical indicators and analysis based on most latest market data
	Transaction History View history of all your transactions and understand their impact on performance
	Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings
	Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios

Is Bluebird Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bluebird Bio. If investors know Bluebird will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bluebird Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.63)

Revenue Per Share

0.214

Quarterly Revenue Growth

173.535

Return On Assets

(0.15)

Return On Equity

(0.48)

The market value of Bluebird bio is measured differently than its book value, which is the value of Bluebird that is recorded on the company's balance sheet. Investors also form their own opinion of Bluebird Bio's value that differs from its market value or its book value, called intrinsic value, which is Bluebird Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bluebird Bio's market value can be influenced by many factors that don't directly affect Bluebird Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Bluebird Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bluebird Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bluebird Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Bluebird Bio Stock Z Score

Bluebird bio Company Z Score Analysis

Z Score

Sum Of

5 Factors

First Factor

1.2 * (

Working Capital

/

Total Assets )

Second Factor

1.4 * (

Retained Earnings

/

Total Assets )

Thrid Factor

3.3 * (

EBITAD

/

Total Assets )

Fouth Factor

0.6 * (

Market Value of Equity

/

Total Liabilities )

Fifth Factor

0.99 * (

Revenue

/

Total Assets )

Bluebird Z Score Driver Correlations

Bluebird Z Score Peer Comparison

Bluebird Bio Institutional Holders

Bluebird Fundamentals

About Bluebird Bio Fundamental Analysis

Pair Trading with Bluebird Bio

Moving together with Bluebird Stock

Moving against Bluebird Stock

Complementary Tools for Bluebird Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY